Everything below concerns lipogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
=== Upcycling === A March 2022 joint study by scientists Sewon Oh and Erin Stache at Cornell University in Ithaca, New York found a new processing method of upcycling polystyrene to benzoic acid. The process involved irradiation of polystyrene with iron chloride and acetone under white light and oxygen for 20 hours. The scientists also demonstrated a similar scalable commercial process of upcycling polystyrene into valuable small-molecules (like benzoic acid) taking just a few hours.
== Adverse effects == Adverse effects of clorazepate include tolerance, dependence, withdrawal reactions, cognitive impairment, confusion, anterograde amnesia, falls in the elderly, ataxia, hangover effects, and drowsiness. It is unclear whether cognitive deficits resulting from the long-term use of benzodiazepines return to normal or persist indefinitely after withdrawal from benzodiazepines. Benzodiazepines are also known to cause or worsen depression. Paradoxical effects including excitement and paradoxical worsening of seizures can sometimes result from the use of benzodiazepines. Children, the elderly, individuals with a history of alcohol use disorder or a history of aggressive behavior and anger are at greater risk of developing paradoxical reactions to benzodiazepines. In September 2020, the U.S. Food and Drug Administration (FDA) required the boxed warning be updated for all benzodiazepine medicines to describe the risks of non-medical use, addiction, physical dependence, and withdrawal reactions consistently across all the medicines in the class.
=== Plant screening program === In 1955, the NCI in the United States set up the Cancer Chemotherapy National Service Center (CCNSC) to act as a public screening center for anticancer activity in compounds submitted by external institutions and companies. Although the majority of compounds screened were of synthetic origin, one chemist, Jonathan Hartwell, who was employed there from 1958 onwards, had experience with natural product derived compounds, and began a plant screening operation. After some years of informal arrangements, in July 1960, the NCI commissioned the United States Department of Agriculture (USDA) botanists to collect samples from about 1,000 plant species per year. On 21 August 1962, one of those botanists, Arthur S. Barclay, collected bark from a single Pacific yew tree in a forest north of the town of Packwood, Washington, as part of a four-month trip to collect material from over 200 different species. The material was then processed by a number of specialist CCNSC subcontractors, and one of the tree's samples was found to be cytotoxic in a cellular assay on 22 May 1964. Accordingly, in late 1964 or early 1965, the fractionation and isolation laboratory run by Monroe E. Wall in Research Triangle Park, North Carolina, began work on fresh Taxus samples, isolating the active ingredient in September 1966 and announcing their findings at an April 1967 American Chemical Society meeting in Miami Beach. They named the pure compound taxol in June 1967. Wall and his colleague Wani published their results, including the chemical structure, in 1971.
=== Black chuño === Black chuño is obtained directly from the original freezing, trampling, and refreezing process. The product is not washed or exposed to water again; after freezing and trampling, it is simply sun-dried. Black chuño production has less regional variation than white chuño, and is more likely to be kept and consumed by farmers than the more commercialized white chuño.
Sources: en.wikipedia.org
Most newspapers in Hong Kong are written in Chinese. There are also English-language newspapers, the major one being the South China Morning Post, with The Standard serving as a business-oriented alternative. A variety of Chinese-language newspapers are published daily; the most prominent are Ming Pao and Oriental Daily News. Local publications are often partisan, with pro-Beijing or pro-democracy sympathies. The central government has a print-media presence in the territory through the state-owned Ta Kung Pao and Wen Wei Po. Several international publications have regional operations in Hong Kong, including The Wall Street Journal, the Financial Times, USA Today, TimeOut, The Nikkei and Vogue Hong Kong. Four free-to-air television broadcasters operate in the territory; TVB, HKTVE, HOY and Phoenix Television air eight digital channels. TVB, Hong Kong's dominant television network, has an 80% viewer share. Paid television services operated by PCCW offer hundreds of additional channels and cater to a variety of audiences. RTHK is the public broadcaster, providing seven radio channels and six free-to-air television channels. Ten non-domestic broadcasters air programming for the territory's foreign population. Access to media and information over the Internet is not subject to mainland Chinese regulations, including the Great Firewall, but local internet censorship applies.
Margaret Ruth Kidder (October 17, 1948 – May 13, 2018) was a Canadian-American actress and activist. She amassed several film and television credits in her career spanning five decades, including her widely known role as Lois Lane in the original Superman films (1978–1987). Her accolades included two Canadian Film Awards, an Emmy Award, a Genie Award, and a Saturn Award. Born in Yellowknife to a Canadian mother and an American father, Kidder was raised in the Northwest Territories and several Canadian provinces. She began her acting career in the 1960s, appearing in low-budget Canadian productions and winning the Canadian Film Special Award in 1969. She first received attention for appearing in the comedy film Quackser Fortune Has a Cousin in the Bronx (1970), the horror films Sisters (1972), Black Christmas (1974), and The Reincarnation of Peter Proud (1975), and the drama films A Quiet Day in Belfast (1974) and The Great Waldo Pepper (1975). Kidder's international breakthrough came with playing Lois Lane in Superman (1978) and Kathy Lutz in The Amityville Horror (1979), which were blockbuster films. For these roles, she was twice nominated for the Saturn Award for Best Actress, winning in 1978 for Superman. She reprised the role of Lois in three Superman sequels (1980–1987), and also played Rita Harris in the comedy film Heartaches (1981) and made her stage debut with the play Bus Stop (1982).
== History == Brilliant Blue FCF was first synthesized in the early 20th century as part of the development of synthetic dyes derived from coal tar and aniline compounds. It gained regulatory prominence in the United States when it was among the first synthetic colorants certified for food use under the Federal Food, Drug, and Cosmetic Act of 1938. In 1969, following a safety review prompted by concerns over certain synthetic colorants, Brilliant Blue FCF was one of the few dyes permanently approved by the U.S. Food and Drug Administration for use in food, drugs, and cosmetics. Its vivid hue, water solubility, chemical stability, and low toxicity contributed to its widespread use. Despite ongoing interest in natural blue alternatives, Brilliant Blue FCF continues to be widely used in commercial products.
When a DU penetrator reaches the interior of an armored vehicle, it catches fire, often igniting ammunition and fuel and possibly causing the vehicle to explode. DU is used by the U.S. Army in 120 mm or 105 mm cannons employed on the M1 Abrams tank. The DU content in various ammunition is 180 grams (6.3 oz) in 20 mm, 200 grams (7.1 oz) in 25 mm, 280 grams (9.9 oz) in 30 mm, 3.5 kilograms (7.7 lb) in 105 mm, and 4.5 kilograms (9.9 lb) in 120 mm penetrators. DU was used during the mid-1990s in the U.S. to make hand grenades, and land mines, but those applications have been discontinued, according to Alliant Techsystems. The US Navy used DU in its 20 mm Phalanx CIWS guns, but switched in the late 1990s to armor-piercing tungsten. Only the US and the UK have acknowledged using DU weapons. The Soviet Union and Russia have used DU weaponry since the 3BM-32 Vant, designed for the 125 mm tank cannons. In 2018, TASS reported that Russia was arming some of its T-80 models with 3BM60 Svinets-2 DU rounds. 782,414 DU rounds were fired during the 1991 war in Iraq, mostly by US forces. In a three-week period of conflict in Iraq during 2003, it was estimated that between 1,000 and 2,000 tonnes of depleted uranium munitions were used. More than 300,000 DU rounds were fired during the 2003 war, the vast majority by US troops.
Primary hypolactasia Primary hypolactasia, or primary lactase deficiency, is genetic, develops in childhood at various ages, and is caused by the absence of a lactase persistence allele. In individuals without the lactase persistence allele, less lactase is produced by the body over time, leading to hypolactasia in adulthood. The frequency of lactase persistence, which allows lactose tolerance, varies enormously worldwide, with the highest prevalence in Northwestern Europe, declines across southern Europe and the Middle East and is low in Asia and most of Africa, although it is common in pastoralist populations from Africa. Secondary hypolactasia Secondary hypolactasia or secondary lactase deficiency, also called acquired hypolactasia or acquired lactase deficiency, is caused by an injury to the small intestine. This form of lactose intolerance can occur in both infants and lactase persistent adults and is generally reversible. It may be caused by acute gastroenteritis, celiac disease, Crohn's disease, ulcerative colitis, chemotherapy, intestinal parasites (such as giardia), or other environmental causes. Primary congenital alactasia Primary congenital alactasia, also called congenital lactase deficiency, is an extremely rare, autosomal recessive enzyme defect that prevents lactase expression from birth. People with congenital lactase deficiency cannot digest lactose from birth, so cannot digest breast milk. This genetic defect is characterized by a complete lack of lactase (alactasia). About 40 cases have been reported worldwide, mainly limited to Finland.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.